Telix Pharmaceuticals Limited (ASX: TLX) has completed the acquisition of a portfolio of assets from antibody engineering firm ImaginAb for $US45 million ($72.5 million). The deal includes a pipeline of cancer drug candidates, a proprietary biologics technology platform, and a protein engineering research facility.
As part of the transaction, Telix paid $US10 million upfront, while $US31 million was settled in equity through the issuance of 2,053,311 fully paid ordinary shares. This acquisition strengthens Telix’s position in oncology and immunotherapy, expanding its capabilities in drug development and precision medicine.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Feb 04, 2025
Feb 04, 2025
Feb 04, 2025
Feb 04, 2025
Feb 03, 2025
Feb 03, 2025
Feb 03, 2025
Feb 03, 2025
Feb 03, 2025
Feb 03, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
